SlideShare a Scribd company logo
1
Out of Specification
By: Shravan Kumar
2
Definition
If the analytical result(s) of a batch or material is/are
falling out side of the established specification
ranges, is called / considered as Out of Specification.
Or
The term OOS test results includes all suspect results
that fall outside the predetermined Specification
3
Out of Specifications
There are lot of guidelines are available for defining
to handle the OOS products/materials/batches as:
 MHRA guideline for OOS
 CDER guideline for OOS
 PIC/S guideline for OOS
4
Out of Specifications
The OOS may be observed during the analysis of:
 Stability study
 Finished API
 Intermediates
 In-process
 Raw materials
 Packing materials
5
Out of Specifications
OOS found due to the following reasons but not
limited to:
OOS
Laboratory
Process
related
Sample
homogeneity
6
Out of Specifications
Laboratory errors:
Laboratory errors
Method of
Analysis
Use of Non
Calibrated
instruments
Error in
calculation
Analyst
error
Instrument
Failure
7
Out of Specifications
Process Related:
Process Related
Operator Error Equipment
Failure
Deviation form
the validated
procedure
Quality of Raw
material /
Intermediate
used
In-Process
Control During
Manufacturing
8
Out of Specifications
Homogeneity sample :
Sample
Homogeneity
Sampling error
Handlin of
samples
Pooling of
sample
9
OOS Investigations
As per MHRA (EU GMP)
Phase – I Investigation
(Primary & extended lab investigation)
Phase – II Investigation
(Manufacturing investigation)
Phase – III Investigation
(Extended manufacturing, Re-sampling
and re-analysis)
Procedures of OOS investigations
As per CDER (US FDA)
Phase – I Investigation
(Primary & extended lab investigation)
Phase – II Investigation
(Manufacturing investigation and re-
sampling and re-analysis)
10
OOS Investigations
Phase – I Investigation: Laboratory investigation
Laboratory investigation is related to the Quality control
department along with rechecking of documents with same
analyst and re-testing with different analyst with original sample.
Phase – I is sub divided in to two sections as:
Phase – Ia (Primary Lab investigation), and
Phase -Ib (Extended Lab investigation)
As per MHRA (EU GMP)
11
OOS Investigations
Phase – II Investigation: Manufacturing Investigations
In manufacturing investigation, production person investigate :
 Process parameters
 Drying parameters
 Input raw materials quality
 training of persons
 Cleaning of equipment
 Environmental information
 Contamination & etc….
As per MHRA (EU GMP)
12
OOS Investigations
Phase – III Investigation: Extended Manufacturing Investigations
In Phase III investigation, Quality Control / Quality Assurance & Production
department investigate the following:
 Sampling error by person
 Authorized for re sampling (if required)
 Re-analysis of re-sampled material with different Analyst
 If root cause found, define the CAPA or if not
 Diverted the matter to R&D / ADL or PD Lab
 Conclusion by all team member (QA, QC, PRD, ADL R&D, PD Lab)
 Decide the fate of batch by QA Head
As per MHRA (EU GMP)
13
OOS Investigations
Re-testing:
The analysis of original sample at the time of phase- I laboratory investigation.
Re-sampling:
The original batch is sampled by QA second time after QA head authorization for re-
analysis.
Re-analysis:
The analysis of re-sampled material for the verification of results, if
manufacturing investigation does not have root cause.
14
OOS Investigations
Phase – I Investigation: Laboratory investigation
Laboratory investigation is related to the Quality control
department along with rechecking of documents with same
analyst and re-testing with different analyst with original
sample.
Phase – II Investigation: Manufacturing investigation
Process related investigation is to be carried out by
Production department along with re-sampling and re-
analysis.
As per CDER (US FDA)
15
OOS Investigations
Phase – I Investigation: Laboratory investigation
 Analyst observed the OOS result
 Re-calculate the results (if required)
 If analytical results remain same
 Report the OOS result to QC In-charge
 Log the OOS
 Start the Primary Laboratory investigation
 Review the documents along with solutions as (Potency / STP
& Specs / buffer solutions / calibration of instruments /
standard solutions / Column efficiency / weights / storage
condition of sample and many more)
16
OOS Investigations
Phase – I Investigation: Laboratory investigation
 If there is no abnormality observed during the primary
lab investigation then
 Report same results and considered as valid OOS and report
 Quality Head review the primary lab investigation and
evaluate for re-testing (if QA Head permits)
 Repeat the analysis as thrice with original sample with
different analyst
 Report the average result of repeat analysis
 Report the average result
17
OOS Investigations
Phase – I Investigation: Laboratory investigation
 If the result complies
 Report as complies and invalidate the OOS
 Release the batch
 If any of result if not complies (among three)
 Report as OOS and continue the OOS
 Report to QA head
QA head will recommend for the Phase – II investigation (manufacturing
investigation)
18
OOS Investigations
Phase – II Investigation: Manufacturing investigation
Production persons shall investigate the following:
 Input quantity of raw material
 Input RM quality
 Process parameters details
 Critical process parameter details (time / temp)
 In-process results
 Out put of the material
 Re-conciliation of raw materials
 Utility pressures
 Calibration / Preventive maintenance of equipment
 Attached ancillaries status
19
OOS Investigations
Phase – II Investigation: Manufacturing investigation
Production persons shall investigate the following:
 Cleaning of equipments
 Training of personnel
 Brain storming with operators
 Contamination verifications
 Environmental review
If there is no assignable cause observed during manufacturing
investigations, same is to be reported to Quality Assurance Head.
20
OOS Investigations
Phase – II Investigation: Manufacturing investigation
QA, QC and production department will evaluate the investigations and after that:
 Sampling procedure review, if suspected
 QA head may recommend for re-sampling
 QC analyst shall analyze the sample as per STP
 Report the result (Pass / Failed)
 If Pass
 Define the CAPA
 Release the Batch
 If failed
 Reject the batch
 Divert the matter to R&D / ADL / PD Lab
21
OOS Investigations
Phase – II Investigation: Manufacturing investigation
R&D / ADL / PD Lab shall:
 Take the user trial with the material
 Investigate the failure based on experiments / experiences
 Various types of experiments
 To find out the root cause
 To identify, is this material can b e reprocessed / reworked
 Make a summary report
 Defined the corrective actions
22
OOS Investigations
Phase – II Investigation: Manufacturing investigation
QA/QC/Production department shall:
 QA head shall define the fate of batch for reprocess / rework /
destruction
 Accept the corrective and preventive actions
 Training to all concerned for root cause / corrective action / preventive
action
 Monitor the activity for corrective actions
 Evaluate the results of corrective actions
 Implement the preventive actions
 Verify the implementation of preventive actions
 After satisfactory implementation close the OOS & CAPA
23
OOS Investigations
All these activity for investigation / corrective actions / preventive
actions should be recorded and reviewed and archived.
24
OOS Investigations
If OOS batch is to be reprocessed / re-work:
 Follow the written approved BMR for re-process / Rework
 Sample as per SOP for sampling of material
 Analyze the material according to the specification and STP
 Evaluate the quality of the batch
 Keep this batch for stability (Accelerated / Long term)
 Evaluate the stability results of the batch
 Communicate the OOS to the customers (as mentioned in to the
Quality agreement)
25
OOS Investigations
Impact of OOS on REGULATORY:
 Stability study required
 OOS should be reported to RA
 OOS batch should not be sold to Regulatory market
 OOS batch can not be blend with fresh approved batch
 OOS batch can not be directly sell to the market
26
Abbreviations
 CDER : Center for drug evaluation and research
 OOS : Out of specification
 RA : Regulatory affairs
 STP : Standard testing procedure
 EU-GMP : European good manufacturing practices
 PIC/s : Pharmaceutical inspection co-operation
scheme
27
Thank You

More Related Content

PPTX
Investigation of OOS and OOT results
PDF
Deviation, OOS & complaint investigation and CAPA
PPTX
Change control oos oot
PDF
Handling of OOS Dr.A. Amsavel
PPTX
CHANGE CONTROL
PPTX
Out of specification (oos)1
PDF
Analytical Method Validation basics by Dr. A. Amsavel
PPTX
Investigation of OOS and OOT results
Deviation, OOS & complaint investigation and CAPA
Change control oos oot
Handling of OOS Dr.A. Amsavel
CHANGE CONTROL
Out of specification (oos)1
Analytical Method Validation basics by Dr. A. Amsavel

What's hot (20)

PPTX
Qualification and validation
PPTX
Validation master plan
PPTX
Ich guideline for stability testing
PPTX
ICH QSEM Guidelines
PPTX
Quality control on secondary packaging materials
PPTX
PPT
PHARMACEUTICAL VALIDATION
PPTX
Pharmaceutical validation ppt Rahul Dalvi
PPTX
IP 2 / UNIT 4 /QUALITY MANAGEMENT SYSTEMS (QMS)
PPTX
USFDA guidelines of glp for non clinical testing laboratories
PPTX
Scale up and post approval changes(supac)
PPTX
Purchase specifications & Maintenance of stores For Raw materials
PPTX
Glp 112070804004
PPTX
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLC
PPTX
INTRODUCTION TO QUALITY BY DESIGN (QBD)
PPTX
Current Good Manufacturing Practices(cGMP) and industrial management
PPTX
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
PPTX
Quality management systems
PPTX
ICH guidelines (Q,S,E,M)
PPTX
Quality Risk Management
Qualification and validation
Validation master plan
Ich guideline for stability testing
ICH QSEM Guidelines
Quality control on secondary packaging materials
PHARMACEUTICAL VALIDATION
Pharmaceutical validation ppt Rahul Dalvi
IP 2 / UNIT 4 /QUALITY MANAGEMENT SYSTEMS (QMS)
USFDA guidelines of glp for non clinical testing laboratories
Scale up and post approval changes(supac)
Purchase specifications & Maintenance of stores For Raw materials
Glp 112070804004
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLC
INTRODUCTION TO QUALITY BY DESIGN (QBD)
Current Good Manufacturing Practices(cGMP) and industrial management
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Quality management systems
ICH guidelines (Q,S,E,M)
Quality Risk Management
Ad

Viewers also liked (20)

PDF
Handling an OOS in a QC Lab
PPT
Handling OOS results
PPTX
Handling of Out of Specification Results
PPT
Good chromatographic practices
PPTX
Integration of chromatographic peaks
PPT
HPLC - Peak integration for chromatography
PPT
Change control
PPT
Back To Basic Gmp
PPTX
Change control
PDF
Data Integrity II - Chromatography data system (CDS) in Pharma
PPT
Gmp change control by amsavel
PPTX
GMP Training: Handling of deviation
PDF
ICH GUIDELINES
PPT
Hplc presentation for class
PPTX
HPLC - High Performance Liquid Chromatography
PPT
HPLC Principle,Instrumentation and Application
PPT
Hplc course (1)
PPT
Lc training basic_hplc_20_a modifi
PPTX
GCP Overview by Compliance Insight, Inc.
PPTX
4 case study
Handling an OOS in a QC Lab
Handling OOS results
Handling of Out of Specification Results
Good chromatographic practices
Integration of chromatographic peaks
HPLC - Peak integration for chromatography
Change control
Back To Basic Gmp
Change control
Data Integrity II - Chromatography data system (CDS) in Pharma
Gmp change control by amsavel
GMP Training: Handling of deviation
ICH GUIDELINES
Hplc presentation for class
HPLC - High Performance Liquid Chromatography
HPLC Principle,Instrumentation and Application
Hplc course (1)
Lc training basic_hplc_20_a modifi
GCP Overview by Compliance Insight, Inc.
4 case study
Ad

Similar to Out of specification shravan (20)

PPTX
Out of Specification OOS.pptx
PPTX
OUT OF SPECIFICATIONS (OOS).pptx
PPTX
QUALITY SYSTEMS
PPSX
Qms Out of Specifications (oos)
PPTX
MHRA_OOS_OOT_Investigation_Training_MHRA
PPT
Out of specifications
PDF
Investigation of out of specifications.pdf
PPT
OUT OF SPECIFICATION.ppt
PPTX
02Good Laboratory Practice (GLP)(1).pptx
PPTX
PPTX
good laboratory practices
PPTX
good laboratory practices
PPTX
Documentation with respect to release of finished pharmaceutical product
PPTX
QMS Seminar.pptx
PPTX
F sterility failure
PPT
Quality Assurance Qual Indicators.ppt
PPT
Good Manufacturing Practices For Quality Control
PDF
Training Program
PDF
Quality management system
PDF
Presentation-on-Handling-OOS-Investigations-Regulatory-Expectations-Dipesh-Sh...
Out of Specification OOS.pptx
OUT OF SPECIFICATIONS (OOS).pptx
QUALITY SYSTEMS
Qms Out of Specifications (oos)
MHRA_OOS_OOT_Investigation_Training_MHRA
Out of specifications
Investigation of out of specifications.pdf
OUT OF SPECIFICATION.ppt
02Good Laboratory Practice (GLP)(1).pptx
good laboratory practices
good laboratory practices
Documentation with respect to release of finished pharmaceutical product
QMS Seminar.pptx
F sterility failure
Quality Assurance Qual Indicators.ppt
Good Manufacturing Practices For Quality Control
Training Program
Quality management system
Presentation-on-Handling-OOS-Investigations-Regulatory-Expectations-Dipesh-Sh...

Recently uploaded (20)

PDF
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
PPTX
Fundamentals of human energy transfer .pptx
PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
PPTX
1 General Principles of Radiotherapy.pptx
PPTX
Neuropathic pain.ppt treatment managment
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PDF
Neuro ED Bet Sexologist in Patna Bihar India Dr. Sunil Dubey
PPTX
CME 2 Acute Chest Pain preentation for education
PPTX
Important Obstetric Emergency that must be recognised
PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PPTX
SKIN Anatomy and physiology and associated diseases
PPT
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPT
Breast Cancer management for medicsl student.ppt
PPTX
ACID BASE management, base deficit correction
DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PPTX
Respiratory drugs, drugs acting on the respi system
PDF
Human Health And Disease hggyutgghg .pdf
PPT
Management of Acute Kidney Injury at LAUTECH
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
Fundamentals of human energy transfer .pptx
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
1 General Principles of Radiotherapy.pptx
Neuropathic pain.ppt treatment managment
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
Neuro ED Bet Sexologist in Patna Bihar India Dr. Sunil Dubey
CME 2 Acute Chest Pain preentation for education
Important Obstetric Emergency that must be recognised
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
SKIN Anatomy and physiology and associated diseases
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Breast Cancer management for medicsl student.ppt
ACID BASE management, base deficit correction
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
Respiratory drugs, drugs acting on the respi system
Human Health And Disease hggyutgghg .pdf
Management of Acute Kidney Injury at LAUTECH
CT Anatomy for Radiotherapy.pdf eryuioooop

Out of specification shravan

  • 2. 2 Definition If the analytical result(s) of a batch or material is/are falling out side of the established specification ranges, is called / considered as Out of Specification. Or The term OOS test results includes all suspect results that fall outside the predetermined Specification
  • 3. 3 Out of Specifications There are lot of guidelines are available for defining to handle the OOS products/materials/batches as:  MHRA guideline for OOS  CDER guideline for OOS  PIC/S guideline for OOS
  • 4. 4 Out of Specifications The OOS may be observed during the analysis of:  Stability study  Finished API  Intermediates  In-process  Raw materials  Packing materials
  • 5. 5 Out of Specifications OOS found due to the following reasons but not limited to: OOS Laboratory Process related Sample homogeneity
  • 6. 6 Out of Specifications Laboratory errors: Laboratory errors Method of Analysis Use of Non Calibrated instruments Error in calculation Analyst error Instrument Failure
  • 7. 7 Out of Specifications Process Related: Process Related Operator Error Equipment Failure Deviation form the validated procedure Quality of Raw material / Intermediate used In-Process Control During Manufacturing
  • 8. 8 Out of Specifications Homogeneity sample : Sample Homogeneity Sampling error Handlin of samples Pooling of sample
  • 9. 9 OOS Investigations As per MHRA (EU GMP) Phase – I Investigation (Primary & extended lab investigation) Phase – II Investigation (Manufacturing investigation) Phase – III Investigation (Extended manufacturing, Re-sampling and re-analysis) Procedures of OOS investigations As per CDER (US FDA) Phase – I Investigation (Primary & extended lab investigation) Phase – II Investigation (Manufacturing investigation and re- sampling and re-analysis)
  • 10. 10 OOS Investigations Phase – I Investigation: Laboratory investigation Laboratory investigation is related to the Quality control department along with rechecking of documents with same analyst and re-testing with different analyst with original sample. Phase – I is sub divided in to two sections as: Phase – Ia (Primary Lab investigation), and Phase -Ib (Extended Lab investigation) As per MHRA (EU GMP)
  • 11. 11 OOS Investigations Phase – II Investigation: Manufacturing Investigations In manufacturing investigation, production person investigate :  Process parameters  Drying parameters  Input raw materials quality  training of persons  Cleaning of equipment  Environmental information  Contamination & etc…. As per MHRA (EU GMP)
  • 12. 12 OOS Investigations Phase – III Investigation: Extended Manufacturing Investigations In Phase III investigation, Quality Control / Quality Assurance & Production department investigate the following:  Sampling error by person  Authorized for re sampling (if required)  Re-analysis of re-sampled material with different Analyst  If root cause found, define the CAPA or if not  Diverted the matter to R&D / ADL or PD Lab  Conclusion by all team member (QA, QC, PRD, ADL R&D, PD Lab)  Decide the fate of batch by QA Head As per MHRA (EU GMP)
  • 13. 13 OOS Investigations Re-testing: The analysis of original sample at the time of phase- I laboratory investigation. Re-sampling: The original batch is sampled by QA second time after QA head authorization for re- analysis. Re-analysis: The analysis of re-sampled material for the verification of results, if manufacturing investigation does not have root cause.
  • 14. 14 OOS Investigations Phase – I Investigation: Laboratory investigation Laboratory investigation is related to the Quality control department along with rechecking of documents with same analyst and re-testing with different analyst with original sample. Phase – II Investigation: Manufacturing investigation Process related investigation is to be carried out by Production department along with re-sampling and re- analysis. As per CDER (US FDA)
  • 15. 15 OOS Investigations Phase – I Investigation: Laboratory investigation  Analyst observed the OOS result  Re-calculate the results (if required)  If analytical results remain same  Report the OOS result to QC In-charge  Log the OOS  Start the Primary Laboratory investigation  Review the documents along with solutions as (Potency / STP & Specs / buffer solutions / calibration of instruments / standard solutions / Column efficiency / weights / storage condition of sample and many more)
  • 16. 16 OOS Investigations Phase – I Investigation: Laboratory investigation  If there is no abnormality observed during the primary lab investigation then  Report same results and considered as valid OOS and report  Quality Head review the primary lab investigation and evaluate for re-testing (if QA Head permits)  Repeat the analysis as thrice with original sample with different analyst  Report the average result of repeat analysis  Report the average result
  • 17. 17 OOS Investigations Phase – I Investigation: Laboratory investigation  If the result complies  Report as complies and invalidate the OOS  Release the batch  If any of result if not complies (among three)  Report as OOS and continue the OOS  Report to QA head QA head will recommend for the Phase – II investigation (manufacturing investigation)
  • 18. 18 OOS Investigations Phase – II Investigation: Manufacturing investigation Production persons shall investigate the following:  Input quantity of raw material  Input RM quality  Process parameters details  Critical process parameter details (time / temp)  In-process results  Out put of the material  Re-conciliation of raw materials  Utility pressures  Calibration / Preventive maintenance of equipment  Attached ancillaries status
  • 19. 19 OOS Investigations Phase – II Investigation: Manufacturing investigation Production persons shall investigate the following:  Cleaning of equipments  Training of personnel  Brain storming with operators  Contamination verifications  Environmental review If there is no assignable cause observed during manufacturing investigations, same is to be reported to Quality Assurance Head.
  • 20. 20 OOS Investigations Phase – II Investigation: Manufacturing investigation QA, QC and production department will evaluate the investigations and after that:  Sampling procedure review, if suspected  QA head may recommend for re-sampling  QC analyst shall analyze the sample as per STP  Report the result (Pass / Failed)  If Pass  Define the CAPA  Release the Batch  If failed  Reject the batch  Divert the matter to R&D / ADL / PD Lab
  • 21. 21 OOS Investigations Phase – II Investigation: Manufacturing investigation R&D / ADL / PD Lab shall:  Take the user trial with the material  Investigate the failure based on experiments / experiences  Various types of experiments  To find out the root cause  To identify, is this material can b e reprocessed / reworked  Make a summary report  Defined the corrective actions
  • 22. 22 OOS Investigations Phase – II Investigation: Manufacturing investigation QA/QC/Production department shall:  QA head shall define the fate of batch for reprocess / rework / destruction  Accept the corrective and preventive actions  Training to all concerned for root cause / corrective action / preventive action  Monitor the activity for corrective actions  Evaluate the results of corrective actions  Implement the preventive actions  Verify the implementation of preventive actions  After satisfactory implementation close the OOS & CAPA
  • 23. 23 OOS Investigations All these activity for investigation / corrective actions / preventive actions should be recorded and reviewed and archived.
  • 24. 24 OOS Investigations If OOS batch is to be reprocessed / re-work:  Follow the written approved BMR for re-process / Rework  Sample as per SOP for sampling of material  Analyze the material according to the specification and STP  Evaluate the quality of the batch  Keep this batch for stability (Accelerated / Long term)  Evaluate the stability results of the batch  Communicate the OOS to the customers (as mentioned in to the Quality agreement)
  • 25. 25 OOS Investigations Impact of OOS on REGULATORY:  Stability study required  OOS should be reported to RA  OOS batch should not be sold to Regulatory market  OOS batch can not be blend with fresh approved batch  OOS batch can not be directly sell to the market
  • 26. 26 Abbreviations  CDER : Center for drug evaluation and research  OOS : Out of specification  RA : Regulatory affairs  STP : Standard testing procedure  EU-GMP : European good manufacturing practices  PIC/s : Pharmaceutical inspection co-operation scheme